Phathom posts $84.7m Q3 revenue as VOQUEZNA hits 2m scripts

Phathom Pharmaceuticals reported 71% year-on-year revenue growth in Q3 2026 and positive operating cash flow for a second consecutive quarter.

White blister packs of medication move on a conveyor belt in a brightly lit, sterile pharmaceutical manufacturing facility, with automated machinery visible in the background.

Phathom Pharmaceuticals has reported net revenues of $84.7 million for the third quarter of 2026, a 71% increase on the $49.5 million recorded in the same period of 2025 and a 14% sequential rise on the second quarter. The New Jersey-based biopharmaceutical company also said it generated positive operating cash flow for the second consecutive quarter, a milestone it described as reflecting a significant financial transformation.

The quarter saw VOQUEZNA, the company's vonoprazan-based acid-suppression franchise, pass two million total prescriptions filled since its launch. Phathom noted that the second million prescriptions were reached less than a year after the first million, suggesting accelerating uptake. Approximately 380,000 scripts were filled in the quarter alone, split between around 248,000 covered and 132,000 cash-pay prescriptions.

Commercial momentum and access initiatives

Covered prescription volume grew roughly 19% sequentially in Q3, reaching approximately 65% of total quarterly scripts, as the company pushed a series of access initiatives under its "Access First" field programme. At the end of the quarter, Phathom introduced a new copay offering through pharmacy partner BlinkRx under which eligible commercially insured patients may pay as little as $0 per prescription. The company said these moves are designed to reduce friction at the point of prescribing and dispensing, which has historically constrained uptake of branded acid-suppressants.

On costs, selling, general and administrative expenses rose to $57.7 million from $51.6 million a year earlier, reflecting increased promotional spend and personnel costs associated with the Access First drive. R&D expenses were $8.7 million, up from $7.0 million, as clinical development spending on new programmes increased. The GAAP net loss narrowed to $13.9 million from $30.0 million in Q3 2025; on a non-GAAP basis, adjusted net income was $3.0 million, compared with an adjusted net loss of $11.2 million in the prior-year quarter. Cash stood at $184.6 million at 30 September.

Phathom reaffirmed its full-year 2026 guidance, targeting net revenues of $310 million to $325 million and a gross margin of approximately 80%.

Pipeline and regulatory landscape

Beyond its existing approvals in erosive and non-erosive GERD and H. pylori eradication, Phathom has moved to extend VOQUEZNA's label. It initiated pHalcon-NERD-302, a registrational Phase 3 study examining as-needed use in non-erosive reflux disease, in late September, with topline results expected in the first quarter of 2028. Separately, topline data from the Phase 2 pHalcon-EoE-201 trial in eosinophilic oesophagitis are expected before the end of 2026.

The company is also defending VOQUEZNA's regulatory exclusivity. A US district court granted Phathom's motion to intervene in litigation brought by BDR Pharmaceuticals challenging the FDA's recognition of ten years of new chemical entity exclusivity for vonoprazan tablets through May 2032. The FDA has opened a public comment docket on the matter, with comments due 23 November 2026.

Vonoprazan is a potassium-competitive acid blocker, a mechanism that acts differently from the proton pump inhibitors that dominate the acid-suppression market. PPI generics are deeply entrenched, but PCAB compounds have shown more consistent acid control in clinical studies, and Phathom is not alone in the space: Takeda, which licensed vonoprazan to Phathom for the US, Canada and Europe, markets the molecule in Japan and other Asian markets under a different brand. The commercial trajectory of VOQUEZNA will be watched closely as a test of whether PCAB technology can achieve meaningful penetration in a Western generic-dominated category.